Its interesting @LHI14 when it comes to Imugene, every time someone throws out questions or analysis pertaining to commercial or financial direction they are met with such responses as "I'm pretty sure discussions are in confidence", they "know what they are doing". Next thing you know they are blindsided a week after a top 20 shareholder lunch with news of a severely discounted capital raise. Well that's fine but for investors such as some in my family who have been patient and well invested for up to 8 years now, this rhetoric is not sufficient. Yes there is overwhelming joy at managements handling of Vaxinia and their relationships with Professor Fong and Kaumaya. But why is it when it comes to all matters commercial and financial, heaven forbid monetary, all these barriers are raised. Why is it Rob Davis of Merck, or Kristi Shaw of Kite, Emma Walmesley of Glaxo Smith Kline, (who expresses the need to have courage of her convictions), and practically all other leading Biotech CEO'S, have a mantra on such topics.
Put simply Imugene need to be more straightforward as to what their intentions are, as Davis was when he came to Merck. Last April, two months before he settled into the captain’s seat, Davis stressed that Merck was “open to any opportunity to add a meaningful asset,” telling investors the company was “open to all forms of deals and we have the capital.” Maybe take a lead from Neuren and NEU'S clear and concise financial direction as a guage on what is required at this of the game. Investors need some financial leadership now, the days of insinuating its all happening behind closed doors are well and truly over. And as far as patients and patience, patients are lining up and screaming for Professor Fong and Professor Kaumaya's life changing medicine, and due to their limited financial structure and corporate depth Imugene has been in a position to dose it out to but a handful of patients, in recent years. Meanwhile big pharma is progressing expansive clinical trials using at times far less impressive oncology, to hundreds if not thousands of patients at a time. Securing enough meaningful data to ensure they obtain FDA approvals as they go. Please don't talk to me about patients, or patience for that matter.
Imugene is a remarkable company having both secured and progressed perhaps the most outstanding IP in todays oncology space, including but not limited to CF33/Vaxinia and Saul Priceman's Oncarlytics arm. But the market is a competitive place, and there is a huge unmet need out there. The opportunity to progress their revolutionary oncolytic viruses as fast as is humanly possible is a necessity now, not just for shareholders, but for cancer sufferers worldwide. Such a mission takes money, and lots of it. Money Imugene currently does not have.
DYOR Seek investment advice as and when required Opinions only
Expand
(20min delay)